Abbott Laboratories $ABT Shares Sold by Fifth Third Wealth Advisors LLC

Fifth Third Wealth Advisors LLC decreased its position in Abbott Laboratories (NYSE:ABT) by 14.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,476 shares of the healthcare product maker’s stock after selling 7,824 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Abbott Laboratories were worth $4,669,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. OP Asset Management Ltd purchased a new position in shares of Abbott Laboratories in the first quarter worth about $18,047,000. Apella Capital LLC boosted its position in Abbott Laboratories by 28.9% in the first quarter. Apella Capital LLC now owns 11,799 shares of the healthcare product maker’s stock valued at $1,142,000 after buying an additional 2,643 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in Abbott Laboratories by 303.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker’s stock worth $454,784,000 after buying an additional 3,330,368 shares during the period. Gilbert Capital Group Inc. raised its position in Abbott Laboratories by 2.9% during the 1st quarter. Gilbert Capital Group Inc. now owns 3,936 shares of the healthcare product maker’s stock worth $404,000 after buying an additional 112 shares during the last quarter. Finally, Hixon Zuercher LLC lifted its stake in Abbott Laboratories by 1.2% during the 1st quarter. Hixon Zuercher LLC now owns 23,537 shares of the healthcare product maker’s stock valued at $2,417,000 after acquiring an additional 278 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott signed a global licensing agreement with ALZpath to incorporate its pTau217 antibody into a blood-based Alzheimer’s diagnostic, a potentially meaningful addition to Abbott’s diagnostics portfolio. Reuters article
• Positive Sentiment: Reports highlighted growing momentum in Abbott’s emerging markets and EPD business, supported by branded generics demand, biosimilar expansion, and new approvals, which points to continued international growth. Article
• Positive Sentiment: MiniMed’s launch of Abbott Instinct sensors across European markets expands Abbott’s diabetes technology reach and reinforces the company’s connected care ecosystem. Article
• Positive Sentiment: Abbott was also featured in bullish commentary as a durable dividend aristocrat with 54 straight years of dividend increases, which may be supporting investor sentiment around the stock. Article
• Neutral Sentiment: Abbott continued to draw investor and analyst attention, with articles noting strong interest and a “Moderate Buy” consensus, but these are more sentiment indicators than new fundamental developments. Zacks article
• Negative Sentiment: A Missouri appeals court decision allowing Abbott’s $495 million preterm baby formula verdict appeal to remain in place keeps a major legal overhang on the shares. Article

Insider Transactions at Abbott Laboratories

In related news, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 27th. The stock was bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by insiders.

Abbott Laboratories Stock Down 0.1%

Shares of ABT opened at $90.46 on Thursday. The firm has a market cap of $157.56 billion, a P/E ratio of 25.34, a PEG ratio of 1.56 and a beta of 0.63. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $138.84. The stock’s 50 day moving average is $89.39 and its two-hundred day moving average is $105.69. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same period in the prior year, the company posted $1.09 EPS. The business’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.8%. Abbott Laboratories’s payout ratio is currently 70.59%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ABT shares. Daiwa Securities Group downgraded shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a report on Wednesday, April 22nd. Royal Bank Of Canada decreased their target price on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. The Goldman Sachs Group lowered their price target on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Mizuho cut their price target on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Finally, BTIG Research reissued a “buy” rating and issued a $131.00 price objective on shares of Abbott Laboratories in a report on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $118.30.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.